PharmaResearch is intensifying its efforts to penetrate the Australian market by providing focused clinical training on its flagship product, 'Rejuran,' to local medical professionals.
The company announced on August 13 that it participated in the 'Aesthetics 2026' international symposium held in Sydney, Australia, where it conducted academic lectures and a 'Rejuran Clinical Masterclass' program centered on Rejuran.
Aesthetics 2026 is an event where dermatologists, plastic surgeons, and aesthetic experts from Australia share the latest advancements in aesthetic medicine and clinical experiences. The symposium is hosted by Dr. Steven Liu, a specialist in aesthetic plastic surgery.
Key speakers at the academic lectures included Dr. Noh Nak-kyung, director of Cheongdam Leaders Dermatology, and Dr. Choi Ho-sung, director of Choi's Dermatology Clinic. They presented treatment plans and procedures based on real clinical cases, focusing on skin barrier improvement, pigmentation, and under-eye skin enhancement.
During the Clinical Masterclass, PharmaResearch highlighted the manufacturing technology and clinical evidence of Rejuran, which is based on its proprietary DNA Optimizing Technology (DOT). The program covered patient selection and consultation, individualized treatment plans, and specific procedural methods that Australian medical professionals can apply in their practices.
In a separate 'K-Session,' the latest clinical trends in K-Aesthetics and the procedural experiences of domestic medical professionals were shared. The focus was on conveying treatment design and procedural approaches tailored to individual patients, beyond just product introductions.
Discussions with Dr. Steven Liu also included potential collaborations for developing academic content suitable for Australian patients and clinical environments, as well as training for medical professionals.
Rejuran made its entry into the Australian market after becoming the first PN formulation to receive product approval from the Therapeutic Goods Administration (TGA) in 2023.
Rejuran is a medical device that utilizes polynucleotides (PN) extracted from salmon as its main ingredient, aimed at improving the regenerative environment of skin tissue. A representative from PharmaResearch stated, "We have confirmed that Rejuran is expanding its influence in the global aesthetic medicine market, including Australia, based on academic achievements and clinical evidence beyond Asia."
Meanwhile, K-Aesthetics is accelerating its global market penetration and continuing its revenue growth. PharmaResearch reported a consolidated revenue of 324.8 billion won and an operating profit of 123.8 billion won for the first half of the year, marking its highest performance for that period. Exports reached 142.8 billion won, a 47% increase compared to the same period last year.
The expansion of Rejuran exports, particularly in Europe, along with a 92% increase in cosmetic exports, has been analyzed as a driving force behind the company's global business growth.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.